Month: August 2021

Following is a summary of the “Stellantis N.V. H1 2021 RESULTS” press release. A PDF of the complete press release is attached to this email. The document is also available in the media section of the Stellantis corporate website: https://www.stellantis.com  Stellantis Reports Record H1 Pro Forma Results with 11.4% Margin, All Segments Profitable. Full-Year Guidance Raised to ~10% Adjusted Operating Income Margin  AttachmentStellantis NV H1 2021 Earnings Release_Final

RESULTS AT JUNE 30TH 2021    Press releaseParis, August 3rd 2021 EXCELLENT PERFORMANCE IN ALL THE BUSINESSES IN Q2 21 AND H1 21 In Q2 21, revenues up +18.2% vs. Q2 20 (+20.5%*), with a strong quarter in Global Banking & Investor Solutions, substantial growth in Financial Services and a rebound in Retail Banking Strong positive jaws effect in all the businesses Underlying gross operating income of EUR 2 billion(1), up 55%(1) vs. Q2 20 Low cost of risk at 11 basis points in Q2 21; continued prudent approach in terms of provisioning Underlying Group net income of EUR 1.35 billion(1), reported Group net income (including IFRIC 21 charges and exceptional items) of EUR 1.44 billion in Q2 21 Profitability (ROTE) at 10.4%(1) and 11.2% in Q2 21 In H1 21, underlying gross operating income of EUR 4.2 billion(1), up +83.4%(1) vs....

SHANGHAI, China, Aug. 03, 2021 (GLOBE NEWSWIRE) — ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), an integrated solutions provider in the health and wellness market in China, today announced the pricing of an underwritten public offering of 10 million American Depositary Shares (“ADSs”) at an offering price of US$0.90 per ADS for gross proceeds to the Company of US$9 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, and assuming the underwriter does not exercise the option to purchase additional ADSs. Each ADS represents four Class A ordinary shares of the Company. The Company intends to use the net proceeds from this offering for investment in its SaaS platform, working capital and general corporate purposes. The closing of the...

OperationalThe fleet utilisation rate in the second quarter of 2021 was 65.8 per cent (Q2 2020: 6.5 per cent). Safe Zephyrus continued the contract for Shell at the Shearwater platform in the UK and was in full operation throughout the quarter. The contract initially had a firm period of 145 days and has to date been extended by the client by additional 16 days. Safe Caledonia has been operating for TotalEnergies at the Elgin platform in the UK since 30 March 2021 and was fully utilised in the quarter. The contract has a firm duration of 162 days and two 15-day options, of which the first available option was exercised on 29 July 2021. Safe Boreas has been operating for CNOOC at Buzzard in the UK since 20 April 2021. After two of the three 30-day options were exercised on 9 July 2021, the contract now has a firm duration of 160 days. ...

GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Details on the presentations can be found below.   Wedbush PacGrow Healthcare Conference Date: Wednesday, August 11, 2021Presentation Time: 8 a.m. ESTWebcast: Click Here   Canaccord Genuity 41st Annual Growth Conference Date: Thursday, August 12, 2021Presentation Time: 9 a.m. ESTWebcast: Click Here The presentations and archived webcasts will also be accessible under “Events Calendar” in the investors section...

SpareBank 1 SMN is presenting 2nd quarter 2021 financial results. Time:    Thursday 12 August at 08:00 AM CETPlace:    Webinar Please register by 11 August on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/424B5C477547425D457940 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 11 August on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/424B5C477549455D477440 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 12 August at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with best supportive care Tecentriq is the first and only cancer immunotherapy to demonstrate positive Phase III results in the adjuvant lung cancer settingBasel, 3 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose...

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technologyPARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents...

ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases Pharmacokinetic data potentially supportive of once-daily dosing An international Phase 2 trial in patients with primary proteinuric kidney diseases will begin enrolling patients in the second half of this year Company to host a Virtual Fibrosis R&D Day on September 20, 2021UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced positive results from its Phase 1 study in healthy volunteers for ANG-3070,...